Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances

On September 23, 2026, Equillium (EQ) shared progress updates at the Stifel Virtual Immunology and Inflammation Forum. The company focused on its pipeline, which centers on local delivery and immune-pathway biology. EQ504 and EQ302 were highlighted, with both in early stages of development.

EQ504 is an oral aryl hydrocarbon receptor (AhR) modulator designed for colonic delivery. The company plans to initiate first subject dosing in Q4 of 2026, targeting Phase I data within six months of study start. The primary biomarker for AhR engagement is CYP1A1 induction in colon biopsies. EQ302, an oral peptide inhibitor of IL-15 and IL-21 for celiac disease, is advancing through IND-enabling work and could enter clinical trials within 12 to 18 months.

Equillium reported $57.2 million in cash and equivalents as of the last report, with the potential to receive a $20 million tranche following first dosing in EQ504. The company aims to improve local efficacy while reducing systemic side effects such as headache and nausea associated with earlier AhR modulation. Chief Scientific Officer Stephen Connelly emphasized the company's focus on mucosal immunology across the gut, lung, and skin, with the goal of identifying well-validated targets for better drug design and delivery.

The company's lead programs are EQ504 and EQ302, with EQ504 targeting inflammatory diseases in the gut and potentially the lung, and EQ302 aimed at celiac disease.